Last reviewed · How we verify
Crodimyl (METHYLCHROMONE)
Crodimyl (generic name: METHYLCHROMONE) is a drug. It is currently in Phase 2 development for Angina pectoris.
Crodimyl works by modulating the activity of a specific cellular pathway to improve blood flow to the heart.
Crodimyl is a small molecule with the chemical name 3-METHYL-4(H)-CHROMEN-4-ONE. It is also known by other names, including Methylchromone, Metilcromona, NSC-76095, and Tricromyl.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | METHYLCHROMONE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Imagine your heart as a muscle that needs oxygen to function properly. Crodimyl helps to improve the delivery of oxygen to the heart muscle by affecting the way blood vessels relax and constrict. This allows for better blood flow and reduces the risk of chest pain.
Approved indications
- Angina pectoris
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Crodimyl CI brief — competitive landscape report
- Crodimyl updates RSS · CI watch RSS
Frequently asked questions about Crodimyl
What is Crodimyl?
How does Crodimyl work?
What is Crodimyl used for?
What is the generic name of Crodimyl?
What development phase is Crodimyl in?
Related
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Angina pectoris
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing